OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Particle engineering enables pipeline molecules to achieve their full potential.
Applying a QbD approach helps address excipient variability and other quality features.
In-vitro and in-silico tools can help predict in-vivo outcomes.
Dosage-level authentication provides an added digital layer of security.
June 08, 2021
FDA has granted fast track designation to a GLP-1/glucagon dual agonist in development by Boehringer Ingelheim and Zealand Pharma for the treatment of NASH.
FDA has granted Janssen breakthrough therapy designation for teclistamab, an investigational bispecific antibody under development for treating relapsed or refractory multiple myeloma.
June 07, 2021
FDA has granted accelerated approval to Biogen for Aduhelm (aducanumab), a new mAb treatment for Alzheimer’ disease.
June 04, 2021
MedPharm’s new facility for process development and small-scale manufacturing is in North Carolina, near its existing R&D center.
Well-defined studies are crucial to effective process development
June 03, 2021
Through the acquisition, Aceto can now offer its customers support throughout the drug development process and access to North American manufacturing for APIs and advanced intermediates.
Aptamer Group and PinotBio have formed a strategic collaboration aimed at the development of new drug conjugates for targeted drug delivery.
The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.
In addition to ADCs, other types of highly potent biologics require specialized manufacturing skills.
Particle engineering is a vital tool in overcoming many formulation challenges, and technological advances are enabling developers to achieve the full potential of pipeline molecules.